DBG
XENE icon

De Burlo Group’s Xenon Pharmaceuticals XENE Stock Holding History

De Burlo Group’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,000
Closed -$304K – 225
2022
Q2 		$304K Buy
+10,000
New +$302K 0.09% 62

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

De Burlo Group's XENE Position: Q3 2022 in Review

De Burlo Group sold out of Xenon Pharmaceuticals (XENE) in Q3 2022, closing a stake of 10,000 shares — an estimated $304K sold.

De Burlo Group first reported a position in XENE in Q2 2022 and held it in 1 quarter. The position peaked at $304K in Q2 2022. 154 funds tracked by Wall St. Rank hold XENE as of Q3 2022.

  • De Burlo Group reported no remaining Xenon Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • De Burlo Group sold 10,000 Xenon Pharmaceuticals shares in Q3 2022, an estimated $304K.
  • De Burlo Group first reported a position in Xenon Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • De Burlo Group's Xenon Pharmaceuticals position peaked at $304K in Q2 2022.
  • 154 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2022.

Based on De Burlo Group's 13F filing for Q3 2022, filed 14 Nov 2022.